Palliative higher-dose radiation improved overall survival in NSCLC

October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29
The article discusses a study which showed improvement in the overall survival rate of patients with non-small cell lung cancer who were treated with higher-dose palliative thoracic radiation. Results for symptom palliation, overall survival, toxicity and re-irradiation rate were evaluated in the study. It also indicated the percentage of patients in the high-dose and low-dose groups who were still alive at one year and after two years.


Related Articles

  • Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial. Beijer, Sandra; van Rossum, Erik; Hupperets, Pierre S.; Spreeuwenberg, Cor; van den Beuken, Marieke; Winkens, Ron A.; Ars, Lisette; van den Borne, Ben E.; de Graeff, Alexander; Dagnelie, Pieter C. // BMC Public Health;2007, Vol. 7 Issue 1, p4 

    Background: Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5′-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength,...

  • A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Besse, B.; Heist, R. S.; Papadmitrakopoulou, V. A.; Camidge, D. R.; Beck, J. T.; Schmid, P.; Mulatero, C.; Miller, N.; Dimitrijevic, S.; Urva, S.; Pylvaenaeinen, I.; Petrovic, K.; Johnson, B. E. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p505 

    Everolimus 2.5 mg/day plus granulocyte colony-stimulating factor was identified as the feasible dose given with standard-dose cisplatin–etoposide for treatment-naive extensive-stage small-cell lung cancer (SCLC). Based on the results of this study and a study of everolimus monotherapy for...

  • Non-small cell lung cancer therapy: safety and efficacy in the elderly. Glotzer, Owen S.; Fabian, Thomas; Chandra, Anurag; Bakhos, Charles T. // Drug, Healthcare & Patient Safety;Apr2013, Vol. 5, p113 

    Background: Our objective was to evaluate and review the current literature on the treatment of non-small cell lung cancer (NSCLC) in the elderly. Methods: We selected recent peer-reviewed articles addressing ageing, cancer treatment in the elderly, and lung cancer treatment in the elderly. We...

  • An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. R. de Boer; Y. Humblet; J. Wolf; L. Nogová; K. Ruffert; T. Milenkova; R. Smith; A. Godwood; J. Vansteenkiste // Annals of Oncology;Mar2009, Vol. 20 Issue 3, p486 

    Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The safety and tolerability of vandetanib plus pemetrexed was assessed in patients with advanced non-small-cell...

  • Treatment of advanced non small cell lung cancer. Bareschino, Maria Anna; Schettino, Clorinda; Rossi, Antonio; Maione, Paolo; Sacco, Paola Claudia; Zeppa, Rosario; Gridelli, Cesare // Journal of Thoracic Disease;Jun2011, Vol. 3 Issue 2, p122 

    Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer (NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of patients will be diagnosed with non operable, advanced-stage disease. Palliative chemotherapy and/or radiotherapy represent...

  • The mathematician versus the malignancy. Dolgin, Elie // Nature Medicine;May2014, Vol. 20 Issue 5, p460 

    The article focuses on Franziska Michor, mathematical biologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, who used a mathematical formula, continuous-time Markov chain to model cell birth and death dynamics, for maximum tolerated dose and dose schedule of Tarceva for...

  • Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Xenidis, Nikolaos; Vardakis, Nikolaos; Varthalitis, Ioannis; Giassas, Stylianos; Kontopodis, Emmanouel; Ziras, Nikolaos; Gioulbasanis, Ioannis; Samonis, George; Kalbakis, Kostas; Georgoulias, Vassilis // Cancer Chemotherapy & Pharmacology;Jul2011, Vol. 68 Issue 1, p63 

    Purpose: To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer. Patients and methods: Thirty-one patients with early relapse after first-line therapy with cisplatin/etoposide were treated with...

  • gefitinib.  // Davis's Drug Guide for Nurses, 9th edition;2005, p470 

    Presents information on gefitinib, an antinoeplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have not responded to platinum or docetaxel-based chemotherapy. Pharmacokinetics; Contraindications and precautions; Adverse reactions...

  • Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC. Maione, Paolo; Rossi, Antonio; Bareschino, Maria Anna; Sacco, Paola Claudia; Schettino, Clorinda; Falanga, Marzia; Barbato, Valentina; Ambrosio, Rita; Gridelli, Cesare // Reviews on Recent Clinical Trials;Jan2011, Vol. 6 Issue 1, p44 

    Platinum-based chemotherapy, with or without the antiangiogenetic drug bevacizumab, is the standard first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib has been recently approved as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics